{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:14Z","timestamp":1792088174000,"version":"4.4.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["0153-00178B"],"award-info":[{"award-number":["0153-00178B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["9065-00252"],"award-info":[{"award-number":["9065-00252"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015223","name":"Danish Diabetes and Endocrine Academy","doi-asserted-by":"publisher","award":["NNF17SA0031406"],"award-info":[{"award-number":["NNF17SA0031406"]}],"id":[{"id":"10.13039\/100015223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Non-alcoholic steatohepatitis (NASH) is emerging as a major cause of hepatocellular carcinoma (HCC), however, it is not resolved if compounds in late-stage clinical development for NASH may have additional therapeutic benefits in NASH-driven HCC (NASH-HCC). Here, we profiled monotherapy with semaglutide (glucagon-like-receptor-1 receptor agonist) and lanifibranor (pan-peroxisome proliferator-activated receptor agonist) in a diet-induced obese (DIO) mouse model of NASH-HCC. Disease progression was characterized in male C57BL\/6\u00a0J mice fed the GAN (Gubra Amylin NASH) diet high in fat, fructose and cholesterol for 12\u201372\u00a0weeks\u00a0(n\u2009=\u200915 per group). Other GAN DIO-NASH-HCC mice fed the GAN diet for 54\u00a0weeks and with biopsy-confirmed NASH (NAFLD Activity Score\u2009\u2265\u20095) and advanced fibrosis (stage F3) received vehicle (n\u2009=\u200916), semaglutide (30\u00a0nmol\/kg, s.c., n\u2009=\u200915), or lanifibranor (30\u00a0mg\/kg, p.o., n\u2009=\u200915) once daily for 14\u00a0weeks. GAN DIO-NASH-HCC mice demonstrated progressive NASH, fibrosis and HCC burden. Tumors presented with histological and molecular signatures of poor prognostic HCC. Consistent with clinical trial outcomes in NASH patients, both lanifibranor and semaglutide improved NASH while only lanifibranor reduced fibrosis in GAN DIO-NASH-HCC mice. Notably, only semaglutide reduced tumor burden in GAN DIO-NASH-HCC mice. In conclusion, the GAN DIO-NASH-HCC mouse is a clinical translational model of NASH-HCC. Semaglutide improves both NASH and tumor burden in GAN DIO-NASH-HCC mice, highlighting the suitability of this preclinical model for profiling novel drug therapies targeting NASH-HCC.<\/jats:p>","DOI":"10.1038\/s41598-023-50328-5","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T14:02:29Z","timestamp":1703772149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis"],"prefix":"10.1038","volume":"13","author":[{"given":"Henrik H.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Pors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja W.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogens","family":"Vyberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"N\u00f8hr-Meldgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte Hasle","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Or\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R\u00f8nn","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Lewinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias B.","family":"M\u00f8llerh\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Nygaard","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Feigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"issue":"4","key":"50328_CR1","doi-asserted-by":"publisher","first-page":"100305","DOI":"10.1016\/j.jhepr.2021.100305","volume":"3","author":"ZM Younossi","year":"2021","unstructured":"Younossi, Z. M. & Henry, L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep. 3(4), 100305 (2021).","journal-title":"JHEP Rep."},{"key":"50328_CR2","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.metabol.2015.11.008","volume":"65","author":"GT Brown","year":"2016","unstructured":"Brown, G. T. & Kleiner, D. E. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism. 65, 1080\u20131086 (2016).","journal-title":"Metabolism."},{"issue":"2","key":"50328_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/J.JHEP.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi, H. et al. Global burden of liver disease: 2023 update. J. Hepatol. 79(3), 516\u2013537. https:\/\/doi.org\/10.1016\/J.JHEP.2023.03.017 (2023).","journal-title":"J. Hepatol."},{"key":"50328_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"50328_CR5","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/liv.14087","volume":"39","author":"B Bengtsson","year":"2019","unstructured":"Bengtsson, B., St\u00e5l, P., Wahlin, S., Bj\u00f6rkstr\u00f6m, N. K. & Hagstr\u00f6m, H. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. Liver Int. 39, 1098\u20131108 (2019).","journal-title":"Liver Int."},{"key":"50328_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"D Huang","year":"2021","unstructured":"Huang, D., El-Serag, H. & Loomba, R. Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 18, 223\u2013238 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"50328_CR7","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","volume":"75","author":"GN Ioannou","year":"2021","unstructured":"Ioannou, G. N. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 75, 1476\u20131484 (2021).","journal-title":"J Hepatol."},{"key":"50328_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. Non-alcoholic fatty liver disease\u2014A global public health perspective. J. Hepatol. 70, 531\u2013544 (2019).","journal-title":"J. Hepatol."},{"key":"50328_CR9","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/apt.15464","volume":"50","author":"S Gawrieh","year":"2019","unstructured":"Gawrieh, S. et al. Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: A United States multicentre study. Aliment. Pharmacol. Ther. 50, 809\u2013821 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"50328_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1158\/1078-0432.CCR-21-1258","volume":"29","author":"M Pinter","year":"2023","unstructured":"Pinter, M., Pinato, D. J., Ramadori, P. & Heikenwalder, M. NASH and hepatocellular carcinoma: Immunology and immunotherapy. Clin. Cancer Res. 29, 513\u2013520 (2023).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"50328_CR11","doi-asserted-by":"publisher","first-page":"HEP17","DOI":"10.2217\/hep-2019-0007","volume":"7","author":"C Roderburg","year":"2020","unstructured":"Roderburg, C., Wree, A., Demir, M., Schmelzle, M. & Tacke, F. The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepat. Oncol. 7(1), HEP17 (2020).","journal-title":"Hepat. Oncol."},{"key":"50328_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 592, 450\u2013456 (2021).","journal-title":"Nature."},{"key":"50328_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100886","volume":"28","author":"PD Agarwal","year":"2023","unstructured":"Agarwal, P. D., Lucey, M. R., Said, A. & Kratz, J. Immunotherapy for HCC: limitations in patients with NASH. Ann. Hepatol. 28, 100886 (2023).","journal-title":"Ann. Hepatol."},{"key":"50328_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1158\/1940-6207.CAPR-20-0200","volume":"13","author":"AS Chung","year":"2020","unstructured":"Chung, A. S. et al. Immune checkpoint inhibition is safe and effective for liver cancer prevention in a mouse model of hepatocellular carcinoma. Cancer Prev. Res. 13, 911\u2013922 (2020).","journal-title":"Cancer Prev. Res."},{"key":"50328_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1053\/j.gastro.2020.09.031","volume":"160","author":"B Heinrich","year":"2021","unstructured":"Heinrich, B. et al. Steatohepatitis impairs T-cell-directed immunotherapies against liver tumors in mice. Gastroenterology. 160, 331-345.e6 (2021).","journal-title":"Gastroenterology."},{"key":"50328_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cmet.2018.10.012","volume":"29","author":"MA Febbraio","year":"2019","unstructured":"Febbraio, M. A. et al. Preclinical models for studying NASH-driven HCC: How useful are they?. Cell Metab. 29, 18\u201326 (2019).","journal-title":"Cell Metab."},{"issue":"12","key":"50328_CR17","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/s42255-022-00700-y","volume":"4","author":"S Gallage","year":"2022","unstructured":"Gallage, S. et al. A researcher\u2019s guide to preclinical mouse NASH models. Nat. Metab. 4(12), 1632\u20131649 (2022).","journal-title":"Nat. Metab."},{"key":"50328_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12876-020-01356-2","volume":"20","author":"HH Hansen","year":"2020","unstructured":"Hansen, H. H. et al. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol. 20, 210 (2020).","journal-title":"BMC Gastroenterol."},{"key":"50328_CR19","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.3748\/wjg.v25.i33.4904","volume":"25","author":"ML Boland","year":"2019","unstructured":"Boland, M. L. et al. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J. Gastroenterol. 25, 4904\u20134920 (2019).","journal-title":"World J. Gastroenterol."},{"key":"50328_CR20","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/cts.13235","volume":"15","author":"MB M\u00f8llerh\u00f8j","year":"2022","unstructured":"M\u00f8llerh\u00f8j, M. B. et al. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH. Clin. Transl. Sci. 15, 1167\u20131186 (2022).","journal-title":"Clin. Transl. Sci."},{"key":"50328_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","volume":"18","author":"R Vuppalanchi","year":"2021","unstructured":"Vuppalanchi, R., Noureddin, M., Alkhouri, N. & Sanyal, A. J. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat. Rev. Gastroenterol. Hepatol. 18, 373\u2013392 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"50328_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.amjsurg.2019.09.006","volume":"219","author":"M Kwak","year":"2020","unstructured":"Kwak, M. et al. Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: A propensity matched analysis. Am. J. Surg. 219, 504\u2013507 (2020).","journal-title":"Am. J. Surg."},{"key":"50328_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen, L. B. & Lau, J. The discovery and development of liraglutide and semaglutide. Front. Endocrinol. 10, 155 (2019).","journal-title":"Front. Endocrinol."},{"key":"50328_CR24","unstructured":"FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. FDA News Release. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 (2021)."},{"key":"50328_CR25","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. New Engl. J. Med. 384, 1113\u20131124 (2021).","journal-title":"New Engl. J. Med."},{"key":"50328_CR26","doi-asserted-by":"crossref","first-page":"9A","DOI":"10.1016\/j.jhep.2019.10.008","volume":"72","author":"S Francque","year":"2020","unstructured":"Francque, S., Bedossa, P., Ratziu, V., Anstee, Q. & Bugianesi, E. The PanPPAR agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic NASH: results of the NATIVE Phase 2b trial. Hepatology. 72, 9A-11A (2020).","journal-title":"Hepatology."},{"key":"50328_CR27","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/hep4.1356","volume":"3","author":"A Guillot","year":"2019","unstructured":"Guillot, A. & Tacke, F. Liver macrophages: Old dogmas and new insights. Hepatol. Commun. 3, 730\u2013743 (2019).","journal-title":"Hepatol. Commun."},{"key":"50328_CR28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1309\/RTPM1PY6YGBL2G2R","volume":"128","author":"MM Yeh","year":"2007","unstructured":"Yeh, M. M. & Brunt, E. M. Pathology of nonalcoholic fatty liver disease. Am. J. Clin. Pathol. 128, 837\u2013847 (2007).","journal-title":"Am. J. Clin. Pathol."},{"key":"50328_CR29","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/hep.21531","volume":"45","author":"L Di Tommaso","year":"2007","unstructured":"Di Tommaso, L. et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 45, 725\u2013734 (2007).","journal-title":"Hepatology."},{"key":"50328_CR30","unstructured":"Paradis, V. Tumors of the liver and intrahepatic bile ducts. In WHO Classification of Tumours Editorial Board editor. Digestive System Tumours. WHO Classification of Tumours. 5th edn. International Agency for Research on Cancer 215\u2013264 (2019)."},{"key":"50328_CR31","doi-asserted-by":"publisher","first-page":"10584","DOI":"10.3748\/wjg.v21.i37.10584","volume":"21","author":"M Kanda","year":"2015","unstructured":"Kanda, M., Sugimoto, H. & Kodera, Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J. Gastroenterol. 21, 10584\u201310597 (2015).","journal-title":"World J. Gastroenterol."},{"key":"50328_CR32","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jhep.2009.12.034","volume":"52","author":"L Zender","year":"2010","unstructured":"Zender, L. et al. Cancer gene discovery in hepatocellular carcinoma. J Hepatol. 52, 921\u2013929 (2010).","journal-title":"J Hepatol."},{"key":"50328_CR33","first-page":"1","volume":"13","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Liu, D., Zhang, T. & Xia, L. FGF\/FGFR signaling in hepatocellular carcinoma: From carcinogenesis to recent therapeutic intervention. Cancers 13, 1\u201322 (2021).","journal-title":"Cancers"},{"key":"50328_CR34","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","volume":"69","author":"Y Hoshida","year":"2009","unstructured":"Hoshida, Y. et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69, 7385\u20137392 (2009).","journal-title":"Cancer Res."},{"key":"50328_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 462, 108\u2013112 (2009).","journal-title":"Nature."},{"key":"50328_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2164-15-74","volume":"15","author":"A Herbst","year":"2014","unstructured":"Herbst, A. et al. Comprehensive analysis of \u03b2-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt\/\u03b2-catenin signaling. BMC Genom. 15, 1\u201315 (2014).","journal-title":"BMC Genom."},{"key":"50328_CR37","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/gutjnl-2017-315448","volume":"68","author":"N Senni","year":"2019","unstructured":"Senni, N. et al. \u03b2-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut 68, 322\u2013334 (2019).","journal-title":"Gut"},{"key":"50328_CR38","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41575-022-00620-y","volume":"19","author":"P Johnson","year":"2022","unstructured":"Johnson, P., Zhou, Q., Dao, D. Y. & Lo, Y. M. D. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 19, 670\u2013681 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"50328_CR39","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"50328_CR40","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/hep.30506","volume":"70","author":"J Cai","year":"2019","unstructured":"Cai, J., Zhang, X.-J. & Li, H. The role of innate immune cells in nonalcoholic steatohepatitis. Hepatology 70, 1026\u20131037 (2019).","journal-title":"Hepatology"},{"key":"50328_CR41","doi-asserted-by":"crossref","unstructured":"Daemen, S., Gainullina, A., Kalugotla, G., He, L., Chan, M. M., Beals, J. W., et al. Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH. Cell Rep. 41 (2022).","DOI":"10.1016\/j.celrep.2022.111660"},{"key":"50328_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","volume":"16","author":"K Kazankov","year":"2019","unstructured":"Kazankov, K. et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat. Rev. Gastroenterol. Hepatol. 16, 145\u2013159 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"50328_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115922","volume":"9","author":"W Liang","year":"2014","unstructured":"Liang, W. et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One. 9, e115922 (2014).","journal-title":"PLoS One."},{"key":"50328_CR44","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.drudis.2017.06.007","volume":"22","author":"HH Hansen","year":"2017","unstructured":"Hansen, H. H. et al. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov. Today. 22, 1707\u20131718 (2017).","journal-title":"Drug Discov. Today."},{"key":"50328_CR45","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.bbadis.2018.04.024","volume":"1865","author":"H Denk","year":"2019","unstructured":"Denk, H., Abuja, P. & Zatloukal, K. Animal models of NAFLD from the pathologist\u2019s point of view. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 929\u2013942 (2019).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"50328_CR46","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.ajpath.2014.01.034","volume":"184","author":"JK Dowman","year":"2014","unstructured":"Dowman, J. K. et al. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat\/fructose diet and sedentary lifestyle. Am. J. Pathol. 184, 1550\u20131561 (2014).","journal-title":"Am. J. Pathol."},{"key":"50328_CR47","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba, R., Friedman, S. L. & Shulman, G. I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537\u20132564 (2021).","journal-title":"Cell"},{"key":"50328_CR48","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/ajcn\/69.6.1066","volume":"69","author":"AJ McCullough","year":"1999","unstructured":"McCullough, A. J. & Raguso, C. Effect of cirrhosis on energy expenditure. Am. J. Clin. Nutr. 69, 1066\u20131068 (1999).","journal-title":"Am. J. Clin. Nutr."},{"key":"50328_CR49","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jhep.2004.02.013","volume":"40","author":"SH Caldwell","year":"2004","unstructured":"Caldwell, S. H. & Crespo, D. M. The spectrum expanded: Cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J. Hepatol. 40, 578\u2013584 (2004).","journal-title":"J. Hepatol."},{"key":"50328_CR50","first-page":"197","volume":"23","author":"A Teramoto","year":"2014","unstructured":"Teramoto, A. et al. Comparison of measured and predicted energy expenditure in patients with liver cirrhosis. Asia Pac. J. Clin. Nutr. 23, 197\u2013204 (2014).","journal-title":"Asia Pac. J. Clin. Nutr."},{"key":"50328_CR51","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1210\/jcem-58-6-1125","volume":"58","author":"R Nosadini","year":"1984","unstructured":"Nosadini, R. et al. Carbohydrate and lipid metabolism in cirrhosis. Evidence that hepatic uptake of gluconeogenic precursors and of free fatty acids depends on effective hepatic flow. J. Clin. Endocrinol. Metab. 58, 1125\u20131132 (1984).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"50328_CR52","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/978-3-030-11748-1_14","volume-title":"Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease","author":"HH Hansen","year":"2019","unstructured":"Hansen, H. H. et al. Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis\u2014Clinical translatability and applicability in preclinical drug development. In Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease 2nd edn (eds Krentz, A. et al.) 369\u2013403 (Cham, 2019).","edition":"2"},{"key":"50328_CR53","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/ajg.2013.95","volume":"108","author":"WH Oddy","year":"2013","unstructured":"Oddy, W. H. et al. The western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. Am. J. Gastroenterol. 108, 778\u2013785 (2013).","journal-title":"Am. J. Gastroenterol."},{"key":"50328_CR54","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.clnu.2013.11.003","volume":"33","author":"M Asrih","year":"2014","unstructured":"Asrih, M. & Jornayvaz, F. R. Diets and nonalcoholic fatty liver disease: The good and the bad. Clin. Nutr. 33, 186\u2013190 (2014).","journal-title":"Clin. Nutr."},{"key":"50328_CR55","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrgastro.2010.41","volume":"7","author":"JS Lim","year":"2010","unstructured":"Lim, J. S., Mietus-Snyder, M., Valente, A., Schwarz, J.-M. & Lustig, R. H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat. Rev. Gastroenterol. Hepatol. 7, 251\u2013264 (2010).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"50328_CR56","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1586\/egh.09.32","volume":"3","author":"N Alkhouri","year":"2009","unstructured":"Alkhouri, N., Dixon, L. J. & Feldstein, A. E. Lipotoxicity in nonalcoholic fatty liver disease: Not all lipids are created equal. Expert Rev. Gastroenterol. Hepatol. 3, 445\u2013451 (2009).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"8","key":"50328_CR57","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/S41575-023-00754-7","volume":"20","author":"JM Llovet","year":"2023","unstructured":"Llovet, J. M. et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: Pathogenesis and treatment. Nat. Rev. Gastroenterol. Hepatol. 20(8), 487\u2013503. https:\/\/doi.org\/10.1038\/S41575-023-00754-7 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"50328_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40170-020-00222-9","volume":"8","author":"T Nakagawa","year":"2020","unstructured":"Nakagawa, T. et al. Fructose contributes to the Warburg effect for cancer growth. Cancer Metab. 8(1), 1\u201312 (2020).","journal-title":"Cancer Metab."},{"key":"50328_CR59","doi-asserted-by":"publisher","first-page":"704","DOI":"10.5858\/2010-0524-RA.1","volume":"135","author":"YN Park","year":"2011","unstructured":"Park, Y. N. Update on precursor and early lesions of hepatocellular carcinomas. Arch. Pathol. Lab. Med. 135, 704\u2013715 (2011).","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"4","key":"50328_CR60","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","volume":"75","author":"R Pinyol","year":"2021","unstructured":"Pinyol, R. et al. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 75(4), 865\u2013878 (2021).","journal-title":"J. Hepatol."},{"key":"50328_CR61","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.7150\/jca.44697","volume":"11","author":"JY Zhuo","year":"2020","unstructured":"Zhuo, J. Y. et al. CK19-positive hepatocellular carcinoma is a characteristic subtype. J Cancer 11, 5069\u20135077 (2020).","journal-title":"J Cancer"},{"key":"50328_CR62","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jhep.2016.05.005","volume":"65","author":"A Asgharpour","year":"2016","unstructured":"Asgharpour, A. et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J. Hepatol. 65, 579\u2013588 (2016).","journal-title":"J. Hepatol."},{"issue":"7","key":"50328_CR63","doi-asserted-by":"publisher","first-page":"e22372","DOI":"10.1096\/fj.202200346R","volume":"36","author":"CD Green","year":"2022","unstructured":"Green, C. D. et al. A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. FASEB J. 36(7), e22372 (2022).","journal-title":"FASEB J."},{"key":"50328_CR64","doi-asserted-by":"publisher","first-page":"G345","DOI":"10.1152\/ajpgi.00055.2020","volume":"319","author":"SE Harris","year":"2020","unstructured":"Harris, S. E. et al. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 319, G345\u2013G360 (2020).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"50328_CR65","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.rcl.2022.05.005","volume":"60","author":"E Reizine","year":"2022","unstructured":"Reizine, E., Mul\u00e9, S. & Luciani, A. Focal benign liver lesions and their diagnostic pitfalls. Radiol. Clin. North Am. 60, 755\u2013773 (2022).","journal-title":"Radiol. Clin. North Am."},{"key":"50328_CR66","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/jcp.30582","volume":"237","author":"D Ezhilarasan","year":"2022","unstructured":"Ezhilarasan, D. Hepatic stellate cells in the injured liver: Perspectives beyond hepatic fibrosis. J. Cell Physiol. 237, 436\u2013449 (2022).","journal-title":"J. Cell Physiol."},{"key":"50328_CR67","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1152\/physrev.00041.2003","volume":"84","author":"GK Owens","year":"2004","unstructured":"Owens, G. K., Kumar, M. S. & Wamhoff, B. R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84, 767\u2013801 (2004).","journal-title":"Physiol. Rev."},{"key":"50328_CR68","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/hep.26219","volume":"57","author":"S Coulon","year":"2013","unstructured":"Coulon, S. et al. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology 57, 1793\u20131805 (2013).","journal-title":"Hepatology"},{"key":"50328_CR69","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jhep.2019.02.012","volume":"70","author":"A Hammoutene","year":"2019","unstructured":"Hammoutene, A. & Rautou, P. E. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. J. Hepatol. 70, 1278\u20131291 (2019).","journal-title":"J. Hepatol."},{"key":"50328_CR70","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.endinu.2018.12.009","volume":"66","author":"A Plaza","year":"2019","unstructured":"Plaza, A. et al. Inflammatory stress and altered angiogenesis evoked by very high-fat diets in mouse liver. Endocrinol. Diabetes Nutr. 66, 434\u2013442 (2019).","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"50328_CR71","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1478-3231.2010.02369.x","volume":"31","author":"S Coulon","year":"2011","unstructured":"Coulon, S. et al. Angiogenesis in chronic liver disease and its complications. Liver Int. 31, 146\u2013162 (2011).","journal-title":"Liver Int."},{"key":"50328_CR72","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/gutjnl-2014-308483","volume":"65","author":"E Villa","year":"2016","unstructured":"Villa, E. et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut 65, 861\u2013869 (2016).","journal-title":"Gut"},{"key":"50328_CR73","doi-asserted-by":"crossref","unstructured":"Donne, R., Lujambio, A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology 77 (2023)","DOI":"10.1002\/hep.32740"},{"issue":"6","key":"50328_CR74","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba, R. et al. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: A randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 8(6), 511\u2013522 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"50328_CR75","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1021\/acs.jmedchem.7b01285","volume":"61","author":"B Boubia","year":"2018","unstructured":"Boubia, B. et al. Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) \u03b1\/\u03b3\/\u03b4 triple activators: Discovery of lanifibranor, a new antifibrotic clinical candidate. J. Med. Chem. 61, 2246\u20132265 (2018).","journal-title":"J. Med. Chem."},{"key":"50328_CR76","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","volume":"73","author":"S Lefere","year":"2020","unstructured":"Lefere, S. et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages\u2606. J. Hepatol. 73, 757\u2013770 (2020).","journal-title":"J. Hepatol."},{"key":"50328_CR77","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1210\/en.2012-1937","volume":"154","author":"N Panjwani","year":"2013","unstructured":"Panjwani, N. et al. GLP-1 Receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE ?\/? Mice. Endocrinology. 154, 127\u2013139 (2013).","journal-title":"Endocrinology."},{"key":"50328_CR78","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1210\/en.2017-00812","volume":"159","author":"CB Jensen","year":"2018","unstructured":"Jensen, C. B. et al. Characterization of the glucagonlike peptide-1 receptor in male mouse brain using a novel antibody and in situ hybridization. Endocrinology 159, 665\u2013675 (2018).","journal-title":"Endocrinology"},{"key":"50328_CR79","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1677\/joe.0.1460183","volume":"146","author":"ML Villanueva-Penacarrillo","year":"1995","unstructured":"Villanueva-Penacarrillo, M. L. et al. Glucagon-like peptide-1 binding to rat hepatic membranes. J. Endocrinol. 146, 183\u2013189 (1995).","journal-title":"J. Endocrinol."},{"key":"50328_CR80","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"C Pyke","year":"2014","unstructured":"Pyke, C. et al. GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155, 1280\u20131290 (2014).","journal-title":"Endocrinology"},{"key":"50328_CR81","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2967\/jnumed.106.038679","volume":"48","author":"M K\u00f6rner","year":"2007","unstructured":"K\u00f6rner, M., St\u00f6ckli, M., Waser, B. & Reubi, J. C. GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting. J. Nucl. Med. 48, 736\u2013743 (2007).","journal-title":"J. Nucl. Med."},{"key":"50328_CR82","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/bph.12490","volume":"171","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br. J. Pharmacol. 171, 723\u2013734 (2014).","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"50328_CR83","doi-asserted-by":"publisher","first-page":"e000370","DOI":"10.1136\/bmjgast-2019-000370","volume":"7","author":"H Yokomori","year":"2020","unstructured":"Yokomori, H. & Ando, W. Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis. BMJ Open Gastroenterol. 7(1), e000370 (2020).","journal-title":"BMJ Open Gastroenterol."},{"key":"50328_CR84","doi-asserted-by":"publisher","first-page":"G462","DOI":"10.1152\/ajpgi.00358.2018","volume":"316","author":"MP Suppli","year":"2019","unstructured":"Suppli, M. P. et al. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. Am. J. Physiol. Gastrointest. Liver Physiol. 316, G462\u2013G472 (2019).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"50328_CR85","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2018-02685","volume":"104","author":"VA Fonseca","year":"2019","unstructured":"Fonseca, V. A. et al. Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. J. Clin. Endocrinol. Metab. 104, 4078\u20134086 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"50328_CR86","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429","volume":"5","author":"S Gabery","year":"2020","unstructured":"Gabery, S. et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 5, e133429 (2020).","journal-title":"JCI Insight."},{"key":"50328_CR87","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","volume":"24","author":"KS T\u00f8lb\u00f8l","year":"2018","unstructured":"T\u00f8lb\u00f8l, K. S. et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J. Gastroenterol. 24, 179\u2013194 (2018).","journal-title":"World J. Gastroenterol."},{"key":"50328_CR88","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jhepr.2019.10.008","volume":"1","author":"K Hallsworth","year":"2019","unstructured":"Hallsworth, K. & Adams, L. A. Lifestyle modification in NAFLD\/NASH: Facts and figures. JHEP Rep. 1, 468\u2013479 (2019).","journal-title":"JHEP Rep."},{"issue":"16","key":"50328_CR89","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.3390\/cancers14164051","volume":"14","author":"ERM Zunica","year":"2022","unstructured":"Zunica, E. R. M., Heintz, E. C., Axelrod, C. L. & Kirwan, J. P. Obesity management in the primary prevention of hepatocellular carcinoma. Cancers 14(16), 4051 (2022).","journal-title":"Cancers"},{"key":"50328_CR90","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1038\/onc.2017.38","volume":"36","author":"M Zhou","year":"2017","unstructured":"Zhou, M. et al. The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis. Oncogene. 36, 4135\u20134149 (2017).","journal-title":"Oncogene."},{"key":"50328_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21165722","volume":"21","author":"M Kojima","year":"2020","unstructured":"Kojima, M. et al. Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis. Int. J. Mol. Sci. 21, 1\u201313 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"50328_CR92","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1002\/OBY.23772","volume":"31","author":"C De Barra","year":"2023","unstructured":"De Barra, C. et al. Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function. Obesity 31(7), 1787\u20131797 https:\/\/doi.org\/10.1002\/OBY.23772 (2023).","journal-title":"Obesity"},{"key":"50328_CR93","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrendo.2016.135","volume":"13","author":"B Gross","year":"2017","unstructured":"Gross, B., Pawlak, M., Lefebvre, P. & Staels, B. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nature Rev. Endocrinol. 13, 36\u201349 (2017).","journal-title":"Nature Rev. Endocrinol."},{"key":"50328_CR94","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/0278-6915(93)90225-N","volume":"31","author":"P Bentley","year":"1993","unstructured":"Bentley, P. et al. Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem. Toxicol. 31, 857\u2013907 (1993).","journal-title":"Food Chem. Toxicol."},{"key":"50328_CR95","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00204-017-2094-7","volume":"92","author":"JC Corton","year":"2018","unstructured":"Corton, J. C., Peters, J. M. & Klaunig, J. E. The PPAR\u03b1-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions. Arch. Toxicol. 92, 83\u2013119 (2018).","journal-title":"Arch. Toxicol."},{"key":"50328_CR96","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/j.1440-1746.2012.07213.x","volume":"27","author":"CW Wu","year":"2012","unstructured":"Wu, C. W., Farrell, G. C. & Yu, J. Functional role of peroxisome-proliferator-activated receptor \u03b3 in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 27, 1665\u20131669 (2012).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"50328_CR97","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4254\/wjh.v8.i16.673","volume":"8","author":"MNB Kristiansen","year":"2016","unstructured":"Kristiansen, M. N. B. et al. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J. Hepatol. 8, 673\u2013684 (2016).","journal-title":"World J. Hepatol."},{"issue":"10","key":"50328_CR98","doi-asserted-by":"publisher","first-page":"8494","DOI":"10.3390\/ijms24108494","volume":"24","author":"JA Inia","year":"2023","unstructured":"Inia, J. A. et al. Semaglutide has beneficial effects on non-alcoholic steatohepatitis in Ldlr-\/-.Leiden mice. Int. J. Mol. Sci. 24(10), 8494 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"50328_CR99","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","volume":"62","author":"SE Kanoski","year":"2012","unstructured":"Kanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C. & Hayes, M. R. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 62, 1916\u20131927 (2012).","journal-title":"Neuropharmacology"},{"key":"50328_CR100","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"50328_CR101","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, Austria (2018)."},{"key":"50328_CR102","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"50328_CR103","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.csbj.2022.04.008","volume":"20","author":"CM Ho","year":"2022","unstructured":"Ho, C. M. et al. Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. Comput. Struct. Biotechnol. J. 20, 1752\u20131763 (2022).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"50328_CR104","doi-asserted-by":"publisher","first-page":"E11874","DOI":"10.1073\/pnas.1807305115","volume":"115","author":"G Bidkhori","year":"2018","unstructured":"Bidkhori, G. et al. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. Proc. Natl. Acad. Sci. U. S. A. 115, E11874\u2013E11883 (2018).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"50328_CR105","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","volume":"173","author":"MH Bailey","year":"2018","unstructured":"Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 173, 371-385.e18 (2018).","journal-title":"Cell."},{"key":"50328_CR106","doi-asserted-by":"publisher","DOI":"10.1101\/060012","author":"A Sergushichev","year":"2016","unstructured":"Sergushichev, A. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. bioRxiv. https:\/\/doi.org\/10.1101\/060012 (2016).","journal-title":"bioRxiv."},{"key":"50328_CR107","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 16, 284\u2013287 (2012).","journal-title":"OMICS."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50328-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50328-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50328-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T14:11:18Z","timestamp":1703772678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50328-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["50328"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-50328-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,27]]},"assertion":[{"value":"14 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.H.H., S.P., J.N.M., M.H.N., D.O., M.W.A., M.R.M., M.L.,\u00a0M.B.M., A.N.M. and M.F. are employed by Gubra. H.H.H., J.N.M., M.H.N., D.O., M.W.A., A.N.M. and M.F. are shareholders in Gubra; M.V. is employed by Aalborg University, Copenhagen, Denmark. No other potential conflicts of interest were reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23056"}}